Michael Benkowitz Sells 22,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• Michael Benkowitz, COO of United Therapeutics, sold 22,500 shares of the company's stock on September 29th for a total of $9,490,500 at an average price of $421.80 per share.
• United Therapeutics recently reported earnings of $6.41 per share, missing the consensus estimate and showing an 11.7% increase in revenue year-over-year.
• Bank of America recently raised its price target for United Therapeutics' stock from $314.00 to $463.00, indicating a potential neutral outlook for the company going forward.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) COO Michael Benkowitz sold 22,500 shares of the firm's stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $421.80, for a total transaction of $9,490,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, September 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $416.35, for a total transaction of $9,367,875.00.
• On Monday, September 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $400.56, for a total transaction of $9,012,600.00.
• On Monday, September 8th, Michael Benkowitz sold 5,000 shares of United Therapeutics stock. The stock was sold at an average price of $392.21, for a total transaction of $1,961,050.00.
• On Tuesday, September 9th, Michael Benkowitz sold 11,375 shares of United Therapeutics stock. The stock was sold at an average price of $397.41, for a total transaction of $4,520,538.75.
• On Tuesday, September 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00.

United Therapeutics Stock Performance

United Therapeutics stock traded up $18.97 during midday trading on Wednesday, hitting $438.18. 810,183 shares of the company's stock were exchanged, compared to its average volume of 591,607. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $442.01. The firm has a 50-day moving average of $347.95 and a two-hundred day moving average of $316.38. The company has a market cap of $19.77 billion, a PE ratio of 17.10, a P/E/G ratio of 6.47 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same quarter in the previous year, the company earned $5.85 earnings per share. The firm's revenue was up 11.7% on a year-over-year basis. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics in the 2nd quarter valued at approximately $29,000. WealthCollab LLC raised its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 46 shares during the last quarter. SVB Wealth LLC purchased a new position in United Therapeutics during the 1st quarter worth approximately $32,000. Finally, Geneos Wealth Management Inc. raised its position in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after buying an additional 85 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Bank of America raised their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a report on Tuesday, September 2nd. Royal Bank Of Canada assumed coverage on shares of United Therapeutics in a report on Friday, September 26th. They issued an "outperform" rating and a $569.00 price target on the stock. Wells Fargo & Company raised their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a report on Wednesday, September 3rd. Oppenheimer raised their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Finally, Morgan Stanley lowered their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. Ten research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $449.57.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.